NCT05187429View on ClinicalTrials.gov

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
HIV I Infection
Interventions
DRUG

Nivolumab 10 MG/ML [Opdivo]

Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.

DRUG

Nivolumab 10 MG/ML [Opdivo]

Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.

DRUG

Saline

Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.

Trial Locations (2)

3181

RECRUITING

Alfred Hospital - Department of Infecious Diseases, Melbourne

308433

NOT_YET_RECRUITING

Tan Tock Seng Hospital, Singapore

All Listed Sponsors
collaborator

The Alfred

OTHER

lead

University of Melbourne

OTHER